|Bid||15.47 x 800|
|Ask||15.48 x 1400|
|Day's Range||15.19 - 15.52|
|52 Week Range||12.62 - 19.09|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||5.58|
|Earnings Date||Apr 27, 2022 - May 02, 2022|
|Forward Dividend & Yield||1.40 (8.80%)|
|Ex-Dividend Date||Aug 08, 2022|
|1y Target Est||17.39|
Driven by the growing demand for customized financing, Hercules Capital's (HTGC) top line is expected to keep improving.
Image source: The Motley Fool. Axsome Therapeutics (NASDAQ: AXSM)Q2 2022 Earnings CallAug 09, 2022, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, and welcome to the Axsome Therapeutics conference call.
-- Clinical programs continue to progress, with initial data from Phase 2 study of “off the shelf” SLATE-KRAS and multiple studies within T cell-enhanced SARS-CoV-2 program (CORAL) expected this year -- -- Follow up data from subset of CORAL-BOOST study shows strong neutralizing antibody titers persisted without decay for at least 6 months after single boost administration of self-amplifying mRNA (samRNA) -- -- New credit facility provides financial flexibility entering period of multiple potent